IGPPF yields 15.46% · JNJ yields 2.14%● Live data
📍 IGPPF pulled ahead of the other in Year 1
Combined, IGPPF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IGPPF + JNJ for your $10,000?
Impellam Group plc provides staffing solutions, human capital management, and outsourced people-related services in the United Kingdom, North America, rest of Europe, and Australasia. It operates through four segments: Global Managed Services, STEM, Regional Specialist Staffing, and Healthcare. The Global Managed Services segment engages in the design, implement, coordinate, and report on the talent acquisition process through the provision of multi-disciplinary outsourced recruitment services under the Comensura, Guidant Global, and Flexy brand names. The STEM provides specialist contract and permanent recruitment services of scientists, clinicians, engineers, IT, and digital specialists under the Lorien, Carbon60, Bartech, and SRG brand names. The Regional Specialist Staffing segment offers staffing services for warehouse workers, secretaries, call centre operatives, lawyers, drivers, teachers, chefs, and HR and marketing professionals under the Blue Arrow, Tate, Career Teacher, and Chadwick Nott brand names. The Healthcare segment provides healthcare workforce solutions, including healthcare staffing, managed services, staff bank, occupational health, insourcing, social care, and home care services under the Medacs Healthcare, Global Medics, and Litmus Workforce Solutions brand names. This segment also recruits locum, temporary and permanent doctors, nurses, care workers, and allied health professionals. The company was incorporated in 2008 and is based in Luton, the United Kingdom.
Full IGPPF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.